Abstract
The induction of G1 cell cycle arrest and apoptosis by second-generation selenium compounds (e.g., methylselenol precursors such as methylseleninic acid, MSeA) may contribute to their anti-cancer activities. We have documented previously induction of G1 arrest and apoptosis by MSeA in association with upregulation of cyclin-dependent kinase inhibitor (CDKI) proteins P21Cip1 and/or P27Kip1 in DU145 prostate cancer cells. However, whether these CDKIs play a critical mediator role in G1 arrest and apoptosis by MSeA has not been addressed. In the present work, we show exposure of p53-mutant DU145 cells to sub-apoptotic concentrations of MSeA induced p21cip1 mRNA (3 h) and protein (6 h) much faster than p27kip1 mRNA (12 h) and protein (12 h). Knocking down of P21Cip1 by siRNA completely abolished G1 arrest induction by MSeA in DU145 cells, yet si-p27 RNA had no attenuation effect on the G1 arrest. Depletion of P21Cip1 alone or both P21Cip1 and P27Kip1 increased MSeA-induced caspase-mediated apoptosis. Immunoprecipitation detected increased binding of P21Cip1 to CDK2 and CDK6 in MSeA-exposed DU145 cells. In DU145 xenografts from mice acutely treated with MSeA p.o., the induction of P21Cip1 was observed at 72 h of daily exposure. In p53-wild type LNCaP PCa cells and p53-null PC-3 PCa cells, MSeA modestly and transiently upregulated P21Cip1 protein level, subsiding to basal level by 24 h, without affecting P27Kip1 abundance in the same duration. Si-p21 RNA knockdown in these cells have only a partial effect to reverse G1 arrest induction by MSeA. Together, our data support persistent, p53- independent, P21Cip1 induction as a critical mediator of MSeA-induced G1 arrest in DU145 PCa cells, however, P21Cip1 induction and G1 arrest were not necessary for, and may antagonize, caspase-mediated apoptosis.
Keywords: Selenium, G1 arrest, P21Cip1, siRNA knockdown, prostate cancer
Current Cancer Drug Targets
Title: Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Volume: 10 Issue: 3
Author(s): Z. Wang, H.-J. Lee, Y. Chai, H. Hu, L. Wang, Y. Zhang, C. Jiang and J. Lu
Affiliation:
Keywords: Selenium, G1 arrest, P21Cip1, siRNA knockdown, prostate cancer
Abstract: The induction of G1 cell cycle arrest and apoptosis by second-generation selenium compounds (e.g., methylselenol precursors such as methylseleninic acid, MSeA) may contribute to their anti-cancer activities. We have documented previously induction of G1 arrest and apoptosis by MSeA in association with upregulation of cyclin-dependent kinase inhibitor (CDKI) proteins P21Cip1 and/or P27Kip1 in DU145 prostate cancer cells. However, whether these CDKIs play a critical mediator role in G1 arrest and apoptosis by MSeA has not been addressed. In the present work, we show exposure of p53-mutant DU145 cells to sub-apoptotic concentrations of MSeA induced p21cip1 mRNA (3 h) and protein (6 h) much faster than p27kip1 mRNA (12 h) and protein (12 h). Knocking down of P21Cip1 by siRNA completely abolished G1 arrest induction by MSeA in DU145 cells, yet si-p27 RNA had no attenuation effect on the G1 arrest. Depletion of P21Cip1 alone or both P21Cip1 and P27Kip1 increased MSeA-induced caspase-mediated apoptosis. Immunoprecipitation detected increased binding of P21Cip1 to CDK2 and CDK6 in MSeA-exposed DU145 cells. In DU145 xenografts from mice acutely treated with MSeA p.o., the induction of P21Cip1 was observed at 72 h of daily exposure. In p53-wild type LNCaP PCa cells and p53-null PC-3 PCa cells, MSeA modestly and transiently upregulated P21Cip1 protein level, subsiding to basal level by 24 h, without affecting P27Kip1 abundance in the same duration. Si-p21 RNA knockdown in these cells have only a partial effect to reverse G1 arrest induction by MSeA. Together, our data support persistent, p53- independent, P21Cip1 induction as a critical mediator of MSeA-induced G1 arrest in DU145 PCa cells, however, P21Cip1 induction and G1 arrest were not necessary for, and may antagonize, caspase-mediated apoptosis.
Export Options
About this article
Cite this article as:
Wang Z., Lee H.-J., Chai Y., Hu H., Wang L., Zhang Y., Jiang C. and Lu J., Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells, Current Cancer Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/156800910791190238
DOI https://dx.doi.org/10.2174/156800910791190238 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells
Protein & Peptide Letters Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Current and Future Development of Estrogen Receptor Ligands: Applications in Estrogen-Related Cancers
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Do Insecticides have Adverse Effects on Reproduction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Zinc Tetrafluoroborate Catalyzed Synthesis, Molecular Docking and Cytotoxicity of Pyrrolidinyl Aminophosphonates
Letters in Drug Design & Discovery Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents
Current Drug Targets Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets High Throughput Determination of Gains and Losses of Genetic Material Using High Resolution BAC Arrays and Comparative Genomic Hybridization
Combinatorial Chemistry & High Throughput Screening Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine